

# REXAHN PHARMACEUTICALS, INC.

## FORM 10-Q (Quarterly Report)

Filed 11/03/17 for the Period Ending 09/30/17

Address	15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD, 20850
Telephone	2402685300
CIK	0001228627
Symbol	RNN
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 10-Q**

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File No.:001-34079

**Rexahn Pharmaceuticals, Inc.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or Other Jurisdiction of Incorporation or Organization)*

**11-3516358**

*(I.R.S. Employer Identification No.)*

**15245 Shady Grove Road, Suite 455**

**Rockville, MD 20850**

*(Address of Principal Executive Offices, Including Zip Code)*

**Telephone: (240) 268-5300**

*(Registrant's Telephone Number, Including Area Code)*

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Non-accelerated filer

(Do not check if a smaller reporting company)

Accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 31,725,114 shares as of November 3, 2017.

**REXAHN PHARMACEUTICALS, INC.**  
**TABLE OF CONTENTS**

	<b>Page</b>
<b>PART I</b>	<b>1</b>
<b><u>FINANCIAL INFORMATION</u></b>	
Item 1	1
<u>Financial Statements (Unaudited)</u>	1
1) <u>Condensed Balance Sheet as of September 30, 2017 and December 31, 2016</u>	1
2) <u>Condensed Statement of Operations for the three and nine months ended September 30, 2017 and 2016</u>	2
3) <u>Condensed Statement of Comprehensive Loss for the three and nine months ended September 30, 2017 and 2016</u>	3
4) <u>Condensed Statement of Cash Flows for the nine months ended September 30, 2017 and 2016</u>	4
5) <u>Notes to the Condensed Financial Statements</u>	5
Item 2	26
<u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	26
Item 3	35
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	35
Item 4	35
<u>Controls and Procedures</u>	35
<b>PART II</b>	<b>36</b>
<b><u>OTHER INFORMATION</u></b>	
Item 1A	36
<u>Risk Factors</u>	36
Item 2	36
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	36
Item 6	36
<u>Exhibits</u>	36
<u>SIGNATURES</u>	37

---

**PART I. Financial Information**  
**Item 1. Financial Statements**

**REXAHN PHARMACEUTICALS, INC.**  
Condensed Balance Sheet  
(Unaudited)

	<u>September 30, 2017</u>	<u>December 31, 2016</u>
<b>ASSETS</b>		
<b>Current Assets:</b>		
Cash and cash equivalents	\$ 8,226,189	\$ 11,578,473
Marketable securities	14,977,346	8,737,107
Prepaid expenses and other current assets	1,277,604	608,517
<b>Total Current Assets</b>	<b>24,481,139</b>	<b>20,924,097</b>
<b>Security Deposits</b>	<b>30,785</b>	<b>30,785</b>
<b>Equipment, Net</b>	<b>79,056</b>	<b>88,650</b>
<b>Total Assets</b>	<b>\$ 24,590,980</b>	<b>\$ 21,043,532</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current Liabilities:</b>		
Accounts payable and accrued expenses	\$ 2,338,777	\$ 1,882,500
<b>Deferred Research and Development Arrangement</b>	<b>393,750</b>	<b>450,000</b>
<b>Other Liabilities</b>	<b>61,557</b>	<b>79,204</b>
<b>Warrant Liabilities</b>	<b>6,676,091</b>	<b>1,573,366</b>
<b>Total Liabilities</b>	<b>9,470,175</b>	<b>3,985,070</b>
<b>Commitments and Contingencies</b> (note 14)		
<b>Stockholders' Equity:</b>		
Preferred stock, par value \$0.0001, 10,000,000 authorized shares, none issued and outstanding	-	-
Common stock, par value \$0.0001, 50,000,000 authorized shares, 28,459,805 and 23,736,878 issued and outstanding	2,846	2,374
Additional paid-in capital	151,858,173	132,086,419
Accumulated other comprehensive loss	(13,965)	(6,122)
Accumulated deficit	(136,726,249)	(115,024,209)
<b>Total Stockholders' Equity</b>	<b>15,120,805</b>	<b>17,058,462</b>
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 24,590,980</b>	<b>\$ 21,043,532</b>

(See accompanying notes to the condensed financial statements)

**REXAHN PHARMACEUTICALS, INC.**  
Condensed Statement of Operations  
(Unaudited)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2017	2016	2017	2016
<b>Revenues:</b>	\$ -	\$ -	\$ -	\$ -
<b>Expenses:</b>				
General and administrative	1,574,323	1,418,990	5,004,832	4,490,145
Research and development	2,644,999	2,298,585	7,451,656	8,004,193
<b>Total Expenses</b>	<b>4,219,322</b>	<b>3,717,575</b>	<b>12,456,488</b>	<b>12,494,338</b>
<b>Loss from Operations</b>	<b>(4,219,322)</b>	<b>(3,717,575)</b>	<b>(12,456,488)</b>	<b>(12,494,338)</b>
<b>Other Income (Expense)</b>				
Interest income	60,750	26,145	135,329	83,884
Unrealized gain (loss) on fair value of warrants	3,120,500	967,637	(9,047,831)	3,941,682
Financing expense	-	(143,203)	(333,050)	(313,090)
<b>Total Other Income (Expense)</b>	<b>3,181,250</b>	<b>850,579</b>	<b>(9,245,552)</b>	<b>3,712,476</b>
<b>Net Loss Before Provision for Income Taxes</b>	<b>(1,038,072)</b>	<b>(2,866,996)</b>	<b>(21,702,040)</b>	<b>(8,781,862)</b>
<b>Provision for income taxes</b>	-	-	-	-
<b>Net Loss</b>	<b>\$ (1,038,072)</b>	<b>\$ (2,866,996)</b>	<b>\$ (21,702,040)</b>	<b>\$ (8,781,862)</b>
Net loss per share, basic and diluted	<b>\$ (0.04)</b>	<b>\$ (0.13)</b>	<b>\$ (0.83)</b>	<b>\$ (0.42)</b>
Weighted average number of shares outstanding, basic and diluted	<b>28,459,316</b>	<b>21,644,182</b>	<b>26,121,160</b>	<b>21,075,847</b>

(See accompanying notes to the condensed financial statements)

**REXAHN PHARMACEUTICALS, INC.**  
Condensed Statement of Comprehensive Loss  
(Unaudited)

	<b>For the Three Months Ended</b>		<b>For the Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2016</b>
Net Loss	\$ (1,038,072)	\$ (2,866,996)	\$ (21,702,040)	\$ (8,781,862)
Unrealized gain (loss) on available-for-sale securities	11,740	(6,983)	(7,843)	13,385
<b>Comprehensive Loss</b>	<b>\$ (1,026,332)</b>	<b>\$ (2,873,979)</b>	<b>\$ (21,709,883)</b>	<b>\$ (8,768,477)</b>

(See accompanying notes to the condensed financial statements)

**REXAHN PHARMACEUTICALS, INC.**  
Condensed Statement of Cash Flows  
(Unaudited)

	<b>For the Nine Months Ended September 30,</b>	
	<b>2017</b>	<b>2016</b>
<b>Cash Flows from Operating Activities:</b>		
Net loss	\$ (21,702,040)	\$ (8,781,862)
Adjustments to reconcile net loss to net cash used in operating activities:		
Compensatory stock	31,200	97,649
Depreciation and amortization	30,963	24,123
Amortization of premiums and discounts on marketable securities, net	40,578	21,535
Stock-based compensation	790,006	1,063,589
Amortization of deferred research and development arrangement	(56,250)	(56,250)
Unrealized loss (gain) on fair value of warrants	9,047,831	(3,941,682)
Financing expense	333,050	313,090
Amortization of deferred lease incentive	(9,333)	(9,333)
Deferred lease expenses	(8,314)	(8,787)
Changes in assets and liabilities:		
Prepaid expenses and other assets	(669,087)	419,765
Accounts payable and accrued expenses	456,277	(875,574)
<b>Net Cash Used in Operating Activities</b>	<b>(11,715,119)</b>	<b>(11,733,737)</b>
<b>Cash Flows from Investing Activities:</b>		
Purchase of equipment	(21,369)	(8,263)
Purchase of marketable securities	(15,008,660)	(8,747,423)
Redemption of marketable securities	8,720,000	8,560,000
<b>Net Cash Used in Investing Activities</b>	<b>(6,310,029)</b>	<b>(195,686)</b>
<b>Cash Flows from Financing Activities:</b>		
Issuance of common stock and units, net of issuance costs	9,241,271	10,122,223
Proceeds from exercise of stock warrants	5,354,093	-
Proceeds from exercise of stock options	77,500	-
<b>Net Cash Provided by Financing Activities</b>	<b>14,672,864</b>	<b>10,122,223</b>
<b>Net Decrease in Cash and Cash Equivalents</b>	<b>(3,352,284)</b>	<b>(1,807,200)</b>
<b>Cash and Cash Equivalents – beginning of period</b>	<b>11,578,473</b>	<b>10,199,440</b>
<b>Cash and Cash Equivalents - end of period</b>	<b>\$ 8,226,189</b>	<b>\$ 8,392,240</b>
<b>Supplemental Cash Flow Information</b>		
Non-cash financing and investing activities:		
Warrants issued	\$ 4,107,488	\$ 4,364,110
Warrant liability extinguishment from exercise of warrants	\$ 8,052,594	\$ -

(See accompanying notes to the condensed financial statements)

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**1. Operations and Organization**

*Operations*

Rexahn Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biopharmaceutical company whose principal operations are the discovery, development and commercialization of innovative treatments for cancer. The Company had an accumulated deficit of \$ 136,726,249 at September 30, 2017 and anticipates incurring losses through fiscal year 2017 and beyond. The Company has not yet generated commercial revenues and has funded its operating losses to date through the sale of shares of its common stock and warrants to purchase shares of its common stock, convertible debt, interest income from cash, cash equivalents and marketable securities, and proceeds from reimbursed research and development costs. The Company believes that its cash, cash equivalents, and marketable securities will be sufficient to cover its cash flow requirements for its current activities for at least the next 12 months from the date these financial statements were issued. Management believes it has the capability of managing the Company’s operations within existing cash available by focusing on select research and development activities, selecting projects in conjunction with potential financings and milestones, and efficiently managing the Company’s general and administrative affairs.

*Basis of Presentation*

The accompanying unaudited condensed financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements. In the opinion of the Company’s management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of September 30, 2017 and December 31, 2016 and of the results of operations and comprehensive loss for the three and nine months ended September 30, 2017 and 2016 and cash flows for the nine months ended September 30, 2017 and 2016 have been included. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of results that may be expected for any other interim period or the full fiscal year ending December 31, 2017. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Form 10-K”). Information included in the condensed balance sheet as of December 31, 2016 has been derived from the Company’s audited financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K.

*Use of Estimates*

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Actual results may ultimately differ from these estimates. These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become available.



**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**2. Recent Accounting Pronouncements Affecting the Company**

*Revenue from Contracts with Customers*

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers,” a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard’s core principle is that a company should recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services, and provides a revenue recognition framework in accordance with this principle. On August 12, 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU 2014-09 by one year to December 15, 2017 for annual reporting periods beginning after that date and interim periods therein. The Company expects to adopt this standard for the annual reporting period beginning January 1, 2018. As the Company currently does not have revenue, contracts the Company does not expect the adoption of this standard to have a material impact on the operating results of the Company.

*Leases*

In February 2016, the FASB issued ASU 2016-02, “Leases,” which requires an entity to recognize assets and liabilities arising from leases on the balance sheet and to provide additional disclosures about leasing arrangements. ASU 2016-02 will be effective for reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact the adoption of this guidance will have on its financial statements.

*Compensation-Stock Compensation*

In March 2016, the FASB issued ASU 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share Based Payment Accounting,” which includes multiple provisions intended to simplify various aspects of accounting for share-based payments. The guidance is effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company adopted this guidance for the three months ended March 31, 2017. This pronouncement did not have a material impact on the financial statements.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**3. Marketable Securities**

Marketable securities are considered “available-for-sale” in accordance with FASB Accounting Standards Codification (“ASC”) 320, “Debt and Equity Securities,” and thus are reported at fair value in the Company’s accompanying balance sheet, with unrealized gains and losses excluded from earnings and reported as a separate component of stockholders’ equity. Amounts reclassified out of accumulated other comprehensive income (loss) into realized gains and losses are accounted for on the basis of specific identification and are included in other income or expense in the statement of operations. The Company classifies such investments as current on the balance sheet as the investments are readily marketable and available for use in current operations.

The following table shows the Company’s marketable securities’ adjusted cost, gross unrealized gains and losses, and fair value by significant investment category as of September 30, 2017 and December 31, 2016:

	<b>September 30, 2017</b>			
	Cost Basis	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Commercial Paper	\$ 3,230,566	\$ -	\$ (1,983)	\$ 3,228,583
Corporate Bonds	11,760,745	142	(12,124)	11,748,763
<b>Total Marketable Securities</b>	<b>\$ 14,991,311</b>	<b>\$ 142</b>	<b>\$ (14,107)</b>	<b>\$ 14,977,346</b>

  

	<b>December 31, 2016</b>			
	Cost Basis	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Certificates of Deposit	\$ 720,000	\$ 197	\$ -	\$ 720,197
Commercial Paper	3,987,424	-	(1,684)	3,985,740
Corporate Bonds	4,035,805	-	(4,635)	4,031,170
<b>Total Marketable Securities</b>	<b>\$ 8,743,229</b>	<b>\$ 197</b>	<b>\$ (6,319)</b>	<b>\$ 8,737,107</b>

The Company typically invests in highly-rated securities, with the primary objective of minimizing the potential risk of principal loss. As of September 30, 2017, the Company had three investments of commercial paper with an aggregate fair value of \$3,228,583 and unrealized losses of \$1,983, and 11 corporate bonds with an aggregate fair value of \$11,249,968 and unrealized losses of \$12,124 all of which have been unrealized losses for less than 12 months. The Company does not intend to sell its marketable securities in an unrealized loss position. Based upon these securities’ fair value relative to the cost, high ratings, and volatility of fair value, the Company considers the declines in market value of its marketable securities to be temporary in nature, does not consider any of its investments other-than-temporarily impaired, and anticipates that it will recover the entire amortized cost basis.

The amortized cost basis and fair value of marketable securities by contractual maturity are:

<b>Maturity</b>	<b>Cost Basis</b>	<b>Fair Value</b>
Less than 1 year	\$ 11,963,973	\$ 11,955,906
1 to 5 years	3,027,338	3,021,440
<b>Total Marketable Securities</b>	<b>\$ 14,991,311</b>	<b>\$ 14,977,346</b>

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**4. Prepaid Expenses and Other Current Assets**

	<b>September 30, 2017</b>	December 31, 2016
Deposits on contracts	\$ 611,550	\$ 179,476
Prepaid expenses and other current assets	<u>666,054</u>	<u>429,041</u>
	<u>\$ 1,277,604</u>	<u>\$ 608,517</u>

Deposits on contracts consist of deposits on research and development contracts for services that had not been incurred as of the balance sheet date. Prepaid expenses and other assets include prepaid general and administrative expenses, such as insurance, rent, investor relations fees and compensatory stock issued for services not yet incurred as of the balance sheet date.

**5. Equipment, Net**

	<b>September 30, 2017</b>	December 31, 2016
Furniture and fixtures	\$ 78,794	\$ 78,794
Office and computer equipment	121,817	113,932
Lab equipment	445,134	431,650
Leasehold improvements	<u>133,762</u>	<u>133,762</u>
Total equipment	779,507	758,138
Less: Accumulated depreciation and amortization	<u>(700,451)</u>	<u>(669,488)</u>
Net carrying amount	<u>\$ 79,056</u>	<u>\$ 88,650</u>

**6. Accounts Payable and Accrued Expenses**

	<b>September 30, 2017</b>	December 31, 2016
Trade payables	\$ 462,602	\$ 430,013
Accrued expenses	142,270	141,190
Accrued research and development contract costs	1,163,545	499,889
Payroll liabilities	<u>570,360</u>	<u>811,408</u>
	<u>\$ 2,338,777</u>	<u>\$ 1,882,500</u>

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**7. Deferred Research and Development Arrangement**

*Rexgene Biotech Co., Ltd.*

In 2003, the Company entered into a collaborative research agreement with Rexgene Biotech Co., Ltd. (“Rexgene”), a shareholder. Rexgene is engaged in the development of pharmaceutical products in Asia and has agreed to assist the Company with the research, development and clinical trials necessary for registration of the Company’s drug candidate Archexin® in Asia. This agreement provides Rexgene with exclusive rights to license, sublicense, make, have made, use, sell and import Archexin in Asia. In accordance with the agreement, Rexgene paid the Company a one-time fee of \$1, 500,000 in 2003. The agreement terminates at the later of 20 years or the term of the patent. The amortization reduces research and development expenses for the periods presented.

The Company is using 20 years as its basis for recognition and accordingly, research and development expenses were reduced by \$18,750 for each of the three month periods ended September 30, 2017 and 2016 and \$56,250 for each of the nine month periods ended September 30, 2017 and 2016. The remaining \$393,750 and \$450,000 to be amortized at September 30, 2017 and December 31, 2016, respectively, is reflected as a deferred research and development arrangement on the balance sheet. The payment from Rexgene is being used in the cooperative funding of the costs of development of Archexin. Royalties of 3% of net sales of licensed products will become payable by Rexgene to the Company on a quarterly basis once commercial sales of Archexin begin in Asia. The product is still under development and commercial sales in Asia are not expected to begin until at least 2018.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**8. Other Liabilities***Deferred Lease Incentive*

In accordance with the Company's office lease agreement, as amended and further discussed in Note 14, the Company has been granted leasehold improvement allowances from the lessor to be used for the construction cost of improvements to the leased property, which included architectural and engineering fees, government agency plan check, permit and other fees, sales and use taxes, testing and inspection costs and telephone and data cabling and wiring in the premises. The Company accounted for the benefit of the leasehold improvement allowance as a reduction of rental expense over the term of the office lease.

The following table sets forth the cumulative deferred lease incentive:

	<b>September 30, 2017</b>	December 31, 2016
Deferred lease incentive	<b>\$ 154,660</b>	\$ 154,660
Less accumulated amortization	<b>(132,884)</b>	(123,551)
Balance	<b>\$ 21,776</b>	\$ 31,109

*Deferred Office Lease Expense*

The lease agreement, as amended, provided for an initial annual base rent with annual increases over the lease term. The Company recognizes rental expense on a straight-line basis over the term of the lease, which resulted in a deferred rent liability of \$39,781 and \$48,095 as of September 30, 2017 and December 31, 2016, respectively.

**9. Net Loss per Common Share**

Basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding, plus the number of common share equivalents that would be dilutive. As of September 30, 2017 and December 31, 2016, there were stock options, restricted stock units and warrants to acquire, in the aggregate, 7,166,209 and 7,142,728 shares of the Company's common stock, respectively, that are potentially dilutive. However, diluted loss per share is the same as basic loss per share for all periods presented because the inclusion of common share equivalents would be anti-dilutive.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**10. Common Stock**

The following transactions occurred during the nine months ended September 30, 2017:

*Reverse Stock Split*

On May 5, 2017 the Company effected a one-for- ten reverse stock split of the outstanding shares of the Company's common stock, together with a corresponding proportional reduction in the number of authorized shares of the Company's capital stock. Each ten shares of the Company's common stock, par value \$0.0001 per share, issued and outstanding at the effective time of the reverse stock split were reclassified and combined into one share of common stock par value \$0.0001 per share. The number of shares of common stock and preferred stock the Company is authorized to issue was reduced to 50 million and 10 million, respectively. All share and per share amounts of common stock, stock options, stock warrants and restricted stock units have been restated for all periods to give retroactive effect to the reverse stock split. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Common stock" to "Additional paid-in capital."

*Warrant Exercises*

During the nine months ended September 30, 2017, warrant holders exercised warrants to purchase shares of the Company's common stock for cash of \$ 5,354,093 and the Company issued 1,652,623 shares.

*Stock Option Exercises*

During the nine months ended September 30, 2017, a stock option holder exercised options to purchase shares of the Company's common stock for cash of \$ 77,500 and the Company issued 25,000 shares.

*Compensatory Shares*

During the nine months ended September 30, 2017, the Company issued 15,000 shares to a privately held investor relations firm in exchange for investor relations services. The aggregate market value of the stock issued was \$ 31,200 .

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

*Registered Direct Offering*

On June 12, 2017 the Company closed a registered direct public offering of 3,030,304 shares of common stock and warrants to purchase up to 1,515,152 shares of common stock. The common stock and warrants were sold in units, consisting of a share of common stock and a warrant to purchase 0.5 shares of common stock, at a price of \$3.30 per unit, with an exercise price for the warrants of \$4.00 per share. The total gross proceeds of the offering were \$10,000,003. The warrants issued will become exercisable beginning six months after the closing date, and will remain exercisable until the five-year anniversary of the initial exercise date, and were recorded as liabilities at fair value.

A summary of the allocation of the proceeds of the offering is shown below:

Gross Proceeds:	<u>\$ 10,000,003</u>
Allocated to warrant liabilities	3,673,168
Allocated to common stock and additional paid-in capital	<u>6,326,835</u>
<b>Total allocated gross proceeds:</b>	<b><u>\$ 10,000,003</u></b>

The Company also issued warrants to purchase up to an aggregate 181,818 shares of common stock to the placement agent in the offering. The closing costs for the offering of \$1,193,052 included \$434,320 for the placement agent warrants and \$758,732 for placement agent and other fees. Based on the estimated fair value of the stock and warrants in the units, the Company allocated \$333,050 to financing expense for the warrants and \$860,002 as stock issuance costs.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**11. Stock-Based Compensation**

As of September 30, 2017, the Company had 1,830,443 options to purchase common stock and 47,300 restricted stock units (“RSUs”) outstanding.

At the Company’s Annual Meeting of Shareholders held on June 10, 2013, the Company’s shareholders voted to approve the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (the “2013 Plan”). Under the 2013 Plan, the Company grants equity awards to key employees, directors and consultants of the Company. The Company initially reserved 1,700,000 shares of common stock for issuance pursuant to the 2013 Plan, and on April 11, 2017, the Company’s shareholders approved an increase of 1,700,000 shares of common stock reserved for issuance pursuant to the 2013 Plan. As of September 30, 2017, there were 1,483,443 options and 47,300 RSUs outstanding under the 2013 Plan, and 1,868,507 shares were available for issuance.

On August 5, 2003, the Company established a stock option plan (the “2003 Plan”). Under the 2003 Plan, the Company granted stock options to key employees, directors and consultants of the Company. With the adoption of the 2013 Plan, no new stock options may be issued under the 2003 Plan, but previously issued options under the 2003 Plan remain outstanding until their expiration. As of September 30, 2017, there were 335,000 options outstanding under the 2003 Plan.

In March 2016, the Company granted to a third party an option to purchase up to 12,000 shares of the Company’s common stock. These were the only Company stock options outstanding as of September 30, 2017, that were not issued pursuant to the 2013 Plan or the 2003 Plan.

*Accounting for Awards*

Stock-based compensation expense is the estimated fair value of options and RSUs granted amortized on a straight-line basis over the requisite vesting service period for the entire portion of the award. Total stock-based compensation recognized by the Company for the three and nine months ended September 30, 2017 and 2016 is as follows:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2017	2016	2017	2016
Statement of operations line item:				
General and administrative	\$ 184,914	\$ 232,951	\$ 580,812	\$ 673,064
Research and development	42,700	136,451	209,194	390,525
Total	\$ 227,614	\$ 369,402	\$ 790,006	\$ 1,063,589

No income tax benefit has been recognized in the statement of operations for stock-based compensation arrangements as the Company has provided for a 100% valuation allowance on its deferred tax assets.



**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

*Summary of Stock Option Transactions*

There were 48,326 stock options granted at exercise prices ranging from \$1.84 to \$6.18 with an aggregate fair value of \$738,937 during the nine months ended September 30, 2017. There were 587,637 stock options granted at exercise prices ranging from \$2.60 to \$3.70 with an aggregate fair value of \$1,150,513 during the nine months ended September 30, 2016.

The majority of the option grants to employees vest over a four-year period from the grant date. The vesting period is either (i) 30%, 30% and 40% on the first, second and third anniversaries of the grant date, respectively, or (ii) 25% each on the first four anniversaries of the grant date. With the exception of the options granted in March 2016, which have a three-year term, options generally expire ten years from the date of grant. For the majority of grants to non-employee consultants of the Company, the vesting period is between one and three years, subject to the fulfillment of certain conditions in the individual stock agreements, or 100% upon the occurrence of certain events specified in the individual stock agreements.

The fair value of options at the date of grant was estimated using the Black-Scholes option pricing model. The Company took into consideration guidance under ASC 718, "Compensation-Stock Compensation" and Staff Accounting Bulletin No. 107 ("SAB 107") when reviewing and updating assumptions. The expected volatility is based upon historical volatility of the Company's stock. The expected term is based upon the simplified method as allowed under SAB 107.

The assumptions made in calculating the fair values of options are as follows:

	<b>Nine Months Ended September 30,</b>	
	<b>2017</b>	<b>2016</b>
Black-Scholes assumptions		
Expected dividend yield	<b>0%</b>	0%
Expected volatility	<b>69-79%</b>	31-75%
Risk free interest rate	<b>1.8-2.0%</b>	0.8 -1.4%
Expected term (in years)	<b>5.5-6 years</b>	2-6 years

A summary of stock option activity for the nine months ended September 30, 2017 is as follows:

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding, January 1, 2017	1,690,037	\$ 6.20	7.3 years	\$ -
Granted	483,260	\$ 2.37		
Exercised	(25,000)	\$ 3.10		
Expired	(15,000)	\$ 16.07		
Cancelled	(302,854)	\$ 5.00		
Outstanding, September 30, 2017	1,830,443	\$ 5.35	7.4 years	\$ 194,644
Exercisable, September 30, 2017	1,068,630	\$ 6.60	6.3 years	\$ -

**REXAHN PHARMACEUTICALS, INC.**

## Notes to Condensed Financial Statements

(Unaudited)

The total intrinsic value of options exercised was \$97,872 for the nine months ended September 30, 2017. There were no stock options exercised during the three months ended September 30, 2017 or the three and nine months ended September 30, 2016. The weighted average fair value of the options granted was \$1.53 and \$1.96 for the nine months ended September 30, 2017 and 2016, respectively.

A summary of the Company's unvested options as of September 30, 2017 and changes during the nine months ended September 30, 2017 is presented below:

	<b>2017</b>	
	<b>Number of Options</b>	<b>Weighted Average Fair Value at Grant Date</b>
Unvested at January 1, 2017	897,123	\$ 3.21
Granted	483,260	\$ 1.53
Vested	(458,968)	\$ 3.12
Cancelled	(159,602)	\$ 2.27
Unvested at September 30, 2017	<u>761,813</u>	<u>\$ 2.41</u>

As of September 30, 2017 there was \$ 1,487,756 of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted average vesting period of 2. 6 years.

*Summary of Restricted Stock Unit Transactions*

The Company began granting RSUs to employees in 2017. There were 62,300 RSUs granted with an aggregate fair value of \$114,632 during the nine months ended September 30, 2017. The fair value of an RSU award is the closing price of the Company's common stock on the date of grant.

A summary of RSU activity for the nine months ended September 30, 2017 is as follows:

	<b>Number of RSUs</b>	<b>Weighted</b>
		<b>Average Grant Date Fair Value</b>
Outstanding, January 1, 2017	-	\$ -
Granted	62,300	\$ 1.84
Vested and Released	-	\$ -
Cancelled	(15,000)	\$ 1.84
Outstanding, September 30, 2017	<u>47,300</u>	<u>\$ 1.84</u>

As of September 30, 2017, there was \$ 72,824 of total unrecognized compensation cost related to unvested RSUs which is expected to be recognized over a weighted average vesting period of 3. 4 years.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**12. Warrants**

As of September 30, 2017, warrants to purchase up to 5,288,466 shares were outstanding, having exercise prices ranging from \$3.00 to \$12.80 and expiration dates ranging from December 4, 2017 to December 12, 2022.

	2017		2016	
	Number of warrants	Weighted average exercise price	Number of warrants	Weighted average exercise price
Balance, January 1	5,452,691	\$ 4.92	2,649,199	\$ 7.97
Issued during the period	1,696,970	\$ 4.01	3,194,000	\$ 3.47
Exercised during the period	(1,861,195)	\$ 3.51	-	\$ -
Expired during the period	-	\$ -	(390,508)	\$ 13.72
<b>Balance, September 30</b>	<b>5,288,466</b>	<b>\$ 5.13</b>	<b>5,452,691</b>	<b>\$ 4.92</b>

At September 30, 2017 the weighted average remaining contractual life of the outstanding warrants was 3.8 years.

The warrants issued to investors in the December 2012, November 2015, March 2016 and September 2016 offerings contain a provision for net cash settlement in the event of a fundamental transaction (contractually defined to include a merger, sale of substantially all assets, tender offer or share exchange). Pursuant to the November 2015, March 2016, and September 2016 warrants, if fundamental transaction occurs, then the warrant holder has the option to receive cash, equal to the fair value of the remaining unexercised portion of the warrant. The option is available to holders of the December 2012 warrants only if the consideration issued in the fundamental transaction consists of cash or stock in a non-public company. Due to these contingent redemption provisions, the warrants require liability classification in accordance with ASC 480, "Distinguishing Liabilities from Equity," and are recorded at fair value. The June 2017 warrants contain a provision that allows the holder to opt for cash settlement in a fundamental transaction that was approved by, or required to be approved by, the board of directors of the Company. All of the Company's outstanding warrants provide the holder the option as to the type of consideration received if the holders of common stock receive an option as to their consideration. In addition, all of the Company's outstanding warrants contain a cashless exercise provision that is exercisable only in the event that a registration statement is not effective. That provision may not be operative if an effective registration statement is not available because an exemption under the U.S. securities laws may not be available to issue unregistered shares. As a result, net cash settlement may be required, and the warrants require liability classification.

ASC 820, "Fair Value Measurements and Disclosures," provides requirements for disclosure of liabilities that are measured at fair value on a recurring basis in periods subsequent to the initial recognition. Fair values for warrants were determined using the Binomial Lattice ("Lattice") valuation technique. The Lattice model provides for dynamic assumptions regarding volatility and risk-free interest rates within the total period to maturity. Accordingly, within the contractual term, the Company provided multiple date intervals over which multiple volatilities and risk free interest rates were used. These intervals allow the Lattice model to project outcomes along specific paths that consider volatilities and risk free rates that would be more likely in an early exercise scenario.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

Significant assumptions are determined as follows:

Trading market values—Published trading market values;

Exercise price—Stated exercise price;

Term—Remaining contractual term of the warrant;

Volatility—Historical trading volatility for periods consistent with the remaining terms; and

Risk-free rate—Yields on zero coupon government securities with remaining terms consistent with the remaining terms of the warrants.

Due to the fundamental transaction provision, which could provide for early redemption of the warrants, the model also considered the probability the Company would enter into a fundamental transaction during the remaining term of the warrant. Because the Company is not yet achieving positive cash flow, management believes the probability of a fundamental transaction occurring over the term of the warrant is unlikely and therefore estimates the probability of entering into a fundamental transaction to be 5%. For valuation purposes, the Company also assumed that if such a transaction did occur, it was more likely to occur towards the end of the term of the warrants.

The significant unobservable inputs used in the fair value measurement of the warrants include management's estimate of the probability that a fundamental transaction may occur in the future. Significant increases (decreases) in the probability of occurrence would result in a significantly higher (lower) fair value measurement.

The following table summarizes the fair value of the warrants as of the respective balance sheet dates:

Warrant Issuance:	Fair Value as of:	
	September 30, 2017	December 31, 2016
December 2012 Investor Warrants	\$ 10	\$ 49
July 2013 Investor Warrants	57,422	2,060
October 2013 Investor Warrants	106,316	3,708
January 2014 Investor Warrants	125,862	714
November 2015 Investor Warrants	1,564,850	260,500
November 2015 Placement Agent Warrants	3,882	13,542
March 2016 Investor Warrants	862,700	358,945
March 2016 Placement Agent Warrants	-	21,320
September 2016 Investor Warrants	1,289,457	854,640
September 2016 Placement Agent Warrants	-	57,888
June 2017 Investor Warrants	2,395,683	-
June 2017 Placement Agent Warrants	269,909	-
<b>Total:</b>	<b>\$ 6,676,091</b>	<b>\$ 1,573,366</b>

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

The following table summarizes the number of shares indexed to the warrants as of the respective balance sheet dates:

Warrant Issuance	Number of Shares indexed as of:	
	September 30, 2017	December 31, 2016
December 2012 Investor Warrants	17,430	17,430
July 2013 Investor Warrants	200,000	200,000
October 2013 Investor Warrants	231,732	231,732
January 2014 Investor Warrants	476,193	476,193
November 2015 Investor Warrants	1,250,001	1,250,001
November 2015 Placement Agent Warrants	3,334	83,335
March 2016 Investor Warrants	607,806	1,171,875
March 2016 Placement Agent Warrants	-	78,125
September 2016 Investor Warrants	805,000	1,800,000
September 2016 Placement Agent Warrants	-	144,000
June 2017 Investor Warrants	1,515,152	-
June 2017 Placement Agent Warrants	181,818	-
<b>Total:</b>	<b>5,288,466</b>	<b>5,452,691</b>

The assumptions used in calculating the fair values of the warrants are as follows:

	September 30, 2017	December 31, 2016
Trading market prices	\$ 2.42	\$ 1.40
Estimated future volatility	104%	104%
Dividend	-	-
Estimated future risk-free rate	1.06-2.25%	1.06-2.44%
Equivalent volatility	56-109%	51-60%
Equivalent risk-free rate	0.72-1.52%	0.59-1.25%

**REXAHN PHARMACEUTICALS, INC.**

## Notes to Condensed Financial Statements

(Unaudited)

Changes in the fair value of the warrant liabilities, carried at fair value, reported as “unrealized gain (loss) on fair value of warrants” in the statement of operations:

	For the Three Months Ended		For the Nine Months Ended	
	September 30,		September 30,	
	2017	2016	2017	2016
Expired Warrants	\$ -	\$ -	\$ -	\$ 2,590
December 2012 Investor Warrants	7,306	2,212	39	9,490
July 2013 Investor Warrants	125,686	22,040	(55,362)	115,940
October 2013 Investor Warrants	135,683	30,264	(102,608)	159,871
January 2014 Investor Warrants	177,900	12,190	(125,148)	129,905
November 2015 Investor Warrants	797,688	409,125	(1,304,350)	1,613,750
November 2015 Placement Agent Warrants	1,691	24,683	(366,694)	104,842
March 2016 Investor Warrants	356,472	425,625	(2,873,309)	1,677,891
March 2016 Placement Agent Warrants	-	26,283	(351,899)	112,188
September 2016 Investor Warrants	506,353	12,780	(4,807,246)	12,780
September 2016 Placement Agent Warrants	-	2,435	(503,150)	2,435
June 2017 Investor Warrants	894,076	-	1,277,485	-
June 2017 Placement Agent Warrants	117,645	-	164,411	-
<b>Total:</b>	<b>\$ 3,120,500</b>	<b>\$ 967,637</b>	<b>\$ (9,047,831)</b>	<b>\$ 3,941,682</b>

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**13. Income Taxes**

No provision for federal and state income taxes was required for the three and nine months ended September 30, 2017 and 2016 due to the Company's operating losses and increased deferred tax asset valuation allowance. At September 30, 2017 and December 31, 2016, the Company had unused net operating loss carry-forwards of approximately \$123,515,000 and \$ 111,605 ,000 respectively, which expire at various dates through 2037. Some of this amount may be subject to annual limitations under certain provisions of the Internal Revenue Code related to "changes in ownership."

As of September 30, 2017 and December 31, 2016, the deferred tax assets related to the aforementioned carry-forwards have been fully offset by valuation allowances, because significant utilization of such amounts is not presently expected in the foreseeable future.

Deferred tax assets and valuation allowances consist of:

	<b>September 30, 2017</b>	December 31, 2016
Net Operating Loss Carryforwards	<b>\$ 48,171,000</b>	\$ 43,526,000
Stock Compensation Expense	<b>1,947,000</b>	1,968,000
Book tax differences on assets and liabilities	<b>425,000</b>	547,000
Valuation Allowance	<b>(50,543,000)</b>	(46,041,000)
Net Deferred Tax Assets	<b>\$ -</b>	\$ -

The Company files income tax returns in the U.S. federal and Maryland state jurisdictions. Tax years for fiscal 2014 through 2016 are open and potentially subject to examination by the federal and Maryland state taxing authorities.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**14. Commitments and Contingencies**

- a) The Company has contracted with various vendors for services, with terms that require payments over the terms of the agreements, usually ranging from two to 36 months. The costs to be incurred are estimated and are subject to revision. As of September 30, 2017, the total estimated cost to complete these agreements was approximately \$10,750,000. All of these agreements may be terminated by either party upon appropriate notice as stipulated in the respective agreements.
- b) On June 22, 2009, the Company entered into a License Agreement with Korea Research Institute of Chemical Technology (“KRICT”) to acquire the rights to all intellectual property related to quinoxaline-piperazine derivatives that were synthesized under a Joint Research Agreement. The initial license fee was \$100,000, all of which was paid as of December 31, 2009. The agreement with KRICT calls for a one-time milestone payment of \$1,000,000 within 30 days after the first achievement of marketing approval of the first commercial product arising out of or in connection with the use of KRICT’s intellectual property. As of September 30, 2017, the milestone has not occurred.

c) *Office Space Lease*

On June 5, 2009, the Company entered into a commercial lease agreement for 5,466 square feet of office space in Rockville, Maryland. The lease was amended on June 7, 2013 to extend the term until June 30, 2019.

On July 26, 2014 the lease was amended to add 1,727 square feet of office space for a term beginning on September 1, 2014 and ending on August 31, 2015, which was subsequently renewed through June 30, 2019. Under the lease agreement, the Company pays its allocable portion of real estate taxes and common area operating charges.

Rent paid under the Company’s lease during the three months ended September 30, 2017 and 2016 was \$ 52,172 and \$51 ,823 , respectively, and rent paid during the nine months ended September 30, 2017 and 2016 was \$1 53,968 and 154,426, respectively.

*Laboratory Lease*

On April 20, 2015, the Company signed a five-year lease agreement for 2,552 square feet of laboratory space commencing on July 1, 2015 and ending on June 30, 2020. Under the lease agreement, the Company pays its allocable portion of real estate taxes and common area operating charges. Rent paid under this lease during the three months ended September 30, 2017 and 2016 was \$ 16,244 and \$ 15,771, respectively , and rent paid during the nine months ended September 30, 2017 and 2016 was \$47,787 and \$ 46,395, respectively .



**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

Future rental payments over the next five years for all leases are as follows:

For the remaining three months ending December 31:	2017	\$	68,943
For the year ending December 31:	2018		279,274
	2019		176,080
	2020		34,468
	<b>Total</b>	<b>\$</b>	<b><u>558,765</u></b>

- d) The Company has established a 401(k) plan for its employees. The Company has elected to match 100% of the first 3% of an employee's compensation plus 50% of an additional 2% of the employee's deferral. Expense related to this matching contribution aggregated to \$ 31,453 and \$ 29,114 for the three months ended September 30, 2017 and 2016, respectively, and \$ 102,536 and \$92,203 for the nine months ended September 30, 2017 and 2016, respectively.
- e) In July 2013, the Company entered into an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer Drug Conjugate Systems. RX-21101 is the Company's first drug candidate utilizing this platform. The agreement requires the Company to make payments to the University of Maryland if RX-21101 or any products from the licensed delivery platform achieve development milestones. As of September 30, 2017, no development milestones have occurred.
- f) In October 2013, the Company signed an exclusive license agreement with the Ohio State Innovation Foundation, for a novel oligonucleotide drug delivery platform, Lipid-Coated Albumin Nanoparticle. The agreement requires the Company to make payments to the Ohio State Innovation Foundation if any products from the licensed delivery platform achieve development milestones. As of September 30, 2017, no development milestones have occurred.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**15. Fair Value Measurements**

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

The three levels are described below:

- Level 1 Inputs — Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible by the Company;
- Level 2 Inputs — Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and
- Level 3 Inputs — Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

The following tables present assets and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. There have been no changes in the methodologies used at September 30, 2017 and December 31, 2016.

**Fair Value Measurements at September 30, 2017**

	Total	Level 1	Level 2	Level 3
<b>Assets:</b>				
Commercial Paper	3,228,583	-	3,228,583	-
Corporate Bonds	11,748,763	-	11,748,763	-
<b>Total Assets:</b>	<b>\$ 14,977,346</b>	<b>\$ -</b>	<b>\$ 14,977,346</b>	<b>\$ -</b>
<b>Liabilities:</b>				
Warrant Liabilities	\$ 6,676,091	\$ -	\$ -	\$ 6,676,091

**Fair Value Measurements at December 31, 2016**

	Total	Level 1	Level 2	Level 3
<b>Assets:</b>				
Certificates of Deposit	\$ 720,197	\$ -	\$ 720,197	\$ -
Commercial Paper	3,985,740	-	3,985,740	-
Corporate Bonds	4,031,170	-	4,031,170	-
<b>Total Assets:</b>	<b>\$ 8,737,107</b>	<b>\$ -</b>	<b>\$ 8,737,107</b>	<b>\$ -</b>
<b>Liabilities:</b>				
Warrant Liabilities	\$ 1,573,366	\$ -	\$ -	\$ 1,573,366

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

The fair value of the Company's Level 2 marketable securities is determined by using quoted prices from independent pricing services that use market data for comparable securities in active or inactive markets. A variety of data inputs, including benchmark yields, interest rates, known historical trades and broker dealer quotes are used with pricing models to determine the quoted prices.

The fair value methodology for the warrant liabilities is disclosed in Note 12.

The carrying amounts reported in the financial statements for cash and cash equivalents (Level 1), approximate fair value because of the short term maturity of these financial instruments.

The following table sets forth a reconciliation of changes for the nine months ended September 30, 2017 and 2016 in the fair value of the liabilities classified as Level 3 in the fair value hierarchy:

	<u>Warrant Liabilities</u>
Balance at January 1, 2017	\$ 1,573,366
Additions	4,107,488
Unrealized losses, net	9,047,831
Transfers out of level 3	(8,052,594)
Balance at September 30, 2017	<u>\$ 6,676,091</u>

	<u>Warrant Liabilities</u>
Balance at January 1, 2016	\$ 2,739,163
Additions	4,364,110
Unrealized gains, net	(3,941,682)
Transfers out of level 3	-
Balance at September 30, 2016	<u>\$ 3,161,591</u>

Additions consist of the fair value of warrant liabilities upon issuance. Transfers out of Level 3 for warrant liabilities consist of warrant exercises, where the liability is converted to additional paid-in capital upon exercise. The Company's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstance that caused the transfer.

**REXAHN PHARMACEUTICALS, INC.**

Notes to Condensed Financial Statements

(Unaudited)

**16. Subsequent Events**

On October 17, 2017 the Company closed a registered direct public offering of 3,265,309 shares of common stock and warrants to purchase up to 1,632,654 shares of common stock. The common stock and warrants were sold in units, consisting of a share of common stock and a warrant to purchase 0.5 shares of common stock, at a price of \$2.45 per unit, with an exercise price for the warrants of \$2.85 per share. The total gross proceeds of the offering were \$8,000,007. The warrants issued will become exercisable beginning six months after the closing date, and will remain exercisable until the five-year anniversary of the initial exercise date. The Company also issued warrants to purchase up to 195,919 shares of the Company's common stock, at an exercise price of \$3.06 per share, to designees of the placement agent in the offering.

## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

### OVERVIEW

The following discussion should be read in conjunction with the unaudited condensed financial statements and notes thereto set forth in Item 1 of this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016.

Except for the historical information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. In this Quarterly Report on Form 10-Q, words such as “believe”, “estimate”, “expect”, “anticipate”, “will”, “may”, “intend” and other similar expressions, are intended to identify forward-looking statements. We caution that forward-looking statements are based largely on our expectations and are subject to a number of known and unknown risks and uncertainties that are subject to change based on factors that are, in many instances, beyond our control. Actual results, performance or achievements may differ materially from those contemplated, expressed or implied by the forward-looking statements.

Although we believe that the expectations reflected in our forward-looking statements are reasonable as of the date we make them, actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to:

- our understandings and beliefs regarding the role of certain biological mechanisms and processes in cancer;
- our drug candidates being in early stages of development, including in pre-clinical development;
- our ability to initially develop drug candidates for orphan indications to reduce the time-to-market and take advantage of certain incentives provided by the U.S. Food and Drug Administration;
- our ability to transition from our initial focus on developing drug candidates for orphan indications to candidates for more highly prevalent indications;
- our ability to successfully and timely complete clinical trials for our drug candidates in clinical development;
- uncertainties related to the timing, results and analyses related to our drug candidates in pre-clinical development;
- our ability to obtain the necessary U.S. and international regulatory approvals for our drug candidates;
- our reliance on third-party contract research organizations and other investigators and collaborators for certain research and development services;
- our ability to maintain or engage third-party manufacturers to manufacture, supply, store and distribute supplies of our drug candidates for our clinical trials;

- *our ability to form strategic alliances and partnerships with pharmaceutical companies and other partners for sales and marketing of certain of our product candidates;*
- *demand for and market acceptance of our drug candidates;*
- *the scope and validity of our intellectual property protection for our drug candidates and our ability to develop our candidates without infringing the intellectual property rights of others;*
- *our lack of profitability and the need for additional capital to operate our business; and*
- *other risks and uncertainties, including those set forth herein and in our Annual Report on Form 10-K for the year ended December 31, 2016 under the caption “Risk Factors” and those detailed from time to time in our filings with the Securities and Exchange Commission.*

*These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.*

We are a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer. Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Our clinical pipeline features three oncology product candidates in Phase II clinical development and additional compounds in pre-clinical development. Our strategy is to continue building a significant pipeline of innovative oncology product candidates that we intend to commercialize with partners. Our three clinical stage drug candidates in active development are RX-3117, Supinoxin™ (RX-5902) and Archexin®.

- *RX-3117* is a small molecule nucleoside compound that we believe has therapeutic potential in a broad range of cancers, including pancreatic, bladder, colon, and lung cancer. RX-3117 is being evaluated as monotherapy in a multi-center Phase IIa clinical trial in metastatic pancreatic cancer in patients who are refractory to, or have relapsed after, multiple prior rounds of chemotherapy. We are also planning to evaluate RX-3117 in combination with Abraxane® (nab-paclitaxel) as first line treatment in patients who are newly-diagnosed with metastatic pancreatic cancer and have not had prior cytotoxic treatment. In 2016, we commenced enrollment in another Phase IIa trial in patients with locally advanced or metastatic bladder cancer. This Phase IIa clinical trial is a multi-center open label, single agent study of RX-3117 being conducted at 10 clinical centers in the United States. RX-3117 has received orphan drug designation from the U.S. Food and Drug Administration (the “FDA”) for pancreatic cancer. Orphan drug designation in the United States provides tax incentives for clinical research and a waiver from user fees under certain circumstances. In addition, an orphan drug generally receives seven years of exclusivity after approval for a designated use, during which period the FDA generally cannot approve another product with the same active moiety for the same indication. Rexahn has also received a positive opinion from the European Medicines Agency recommending orphan drug designation in pancreatic cancer.
- *Supinoxin*, or RX-5902, is a potential first-in-class small molecule inhibitor of phosphorylated-p68, a protein that we believe plays a key role in cancer cell growth, progression and metastasis through its interaction with beta-catenin. In February, 2017 we initiated a Phase IIa clinical study of Supinoxin in patients with metastatic triple negative breast cancer (“TNBC”).

- *Archexin* is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. *Archexin* has received orphan drug designation from the FDA for renal cell carcinoma (“RCC”), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer. We are currently conducting a Phase IIa proof-of-concept clinical trial of *Archexin* in patients with metastatic renal cell carcinoma to evaluate its safety and efficacy in combination with AFINITOR® (everolimus).

Since our inception, our efforts and resources have been focused primarily on developing our pharmaceutical technologies, raising capital and recruiting personnel. We have no product sales to date, and we will not generate any product sales until we receive approval from the FDA or equivalent foreign regulatory bodies to begin selling our pharmaceutical candidates. Our major sources of working capital have been proceeds from various private and public financings, and licensing and collaboration agreements with our strategic investors and partners.

On May 5, 2017 the Company effected a one-for-ten reverse stock split of the outstanding shares of the Company’s common stock, together with a corresponding proportional reduction in the number of authorized shares of the Company’s capital stock. See Note 10, “Common Stock—Reverse Stock Split,” in the Notes to Consolidated Financial Statements.

### **Recently Issued Accounting Standards**

See Note 2, “Recent Accounting Pronouncements Affecting the Company,” in the Notes to Condensed Financial Statements for a discussion of recent accounting pronouncements.

### **Results of Operations**

#### ***Comparison of the Three and Nine Months Ended September 30, 2017 and September 30, 2016***

##### ***Total Revenues***

We had no revenues for the three and nine months ended September 30, 2017 or 2016.

##### ***General and Administrative Expenses***

General and administrative expenses consist primarily of salaries and related expenses for executive, finance and other administrative personnel, recruitment expenses, professional fees and other corporate expenses, including business development, investor relations, and general legal activities.

General and administrative expenses increased approximately \$155,000, or 10.9%, to \$1,574,000 for the three months ended September 30, 2017 from \$1,419,000 for the three months ended September 30, 2016. General and administrative expenses increased approximately \$515,000, or 11.4%, to \$5,005,000 for the nine months ended September 30, 2017 from \$4,490,000 for the nine months ended September 30, 2016. The increases were primarily attributable to higher personnel costs and professional fees in 2017.

**Research and Development Expenses**

Research and development expenses increased approximately \$346,000, or 15.1%, to \$2,645,000 for the three months ended September 30, 2017, from \$2,299,000 for the three months ended September 30, 2016. Research and development expenses decreased approximately \$552,000, or 6.9%, to \$7,452,000 for the nine months ended September 30, 2017, from \$8,004,000 for the nine months ended September 30, 2016. In both the three and nine-month periods ended September 30, 2017, we experienced increased clinical trial costs compared to the prior year periods, partially offset by a decrease in personnel expenses. In the three-month period ended September 30, 2017, a new drug manufacturing campaign that began in the third quarter together with the increased clinical trial costs contributed to the overall increase in research and development expenses in the period. Conversely, the increased clinical trial costs in the nine-month period ended September 30, 2017 were more than offset by lower drug manufacturing costs as a result of supplies that were available from earlier manufacturing campaigns. During the nine months ended September 30, 2017, we incurred approximately \$1,324,000 of drug manufacturing costs, primarily as a result of the drug manufacturing campaign that began in the third quarter, compared to approximately \$2,325,000 during the nine months ended September 30, 2016, primarily from large manufacturing campaigns in the early months of 2016. Because the volume and timing of our drug manufacturing does not correlate directly with the level and timing of clinical trial activity, we expect expenses related to drug manufacturing costs to vary from period to period based not only on the progress of clinical trials, but also when we engage in manufacturing activities. We expect research and development expenses to increase in the remaining quarter of 2017 compared to the quarter ended September 30, 2017 due to continued patient enrollment in our clinical trials and new manufacturing campaigns.

The table below summarizes the approximate amounts incurred in each of our research and development projects for the three and nine months ended September 30, 2017 and 2016:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2017	2016	2017	2016
<b>Clinical Candidates:</b>				
RX-3117	\$ 1,245,500	\$ 510,000	\$ 3,134,000	\$ 1,944,700
Supinoxin	492,000	513,300	1,189,800	1,842,700
Archexin	123,200	337,600	422,000	1,421,200
Preclinical, Personnel and Overhead	784,299	937,685	2,705,856	2,795,593
<b>Total Research and Development Expenses</b>	<u>\$ 2,644,999</u>	<u>\$ 2,298,585</u>	<u>\$ 7,451,656</u>	<u>\$ 8,004,193</u>

**Interest Income**

Interest income increased approximately \$35,000 and \$51,000 or 132.4% and \$61.3%, respectively for the three and nine months ended September 30, 2017, respectively, compared to the same periods in 2016. The increases were primarily attributable to higher aggregate balances of cash and cash equivalents and marketable securities and higher interest rates on marketable securities for the three and nine months ended September 30, 2017 compared to the same periods in 2016.



### ***Unrealized Gain (Loss) on Fair Value of Warrants***

Our warrants are recorded as liabilities at fair value, and the warrants are valued using a lattice model. Changes in the fair value of warrants are recorded as an unrealized gain or loss in our statement of operations. During the three months ended September 30, 2017 and 2016, we recorded unrealized gains on the fair value of our warrants of approximately \$3,121,000 and \$968,000. During the nine months ended September 30, 2017, we recorded unrealized (losses) gains on the fair value of warrants of approximately (\$9,048,000) and \$3,942,000 respectively. Estimating fair values of warrants requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the warrants due to related changes to external market factors. The large unrealized gain for the three months ended September 30, 2017 primarily resulted from a decrease in the stock price of the underlying common stock at September 30, 2017 compared to June 30, 2017. The large unrealized loss for the nine months ended September 30, 2017 primarily resulted from a significant increase in the stock price of the underlying common stock at September 30, 2017 compared to December 31, 2016. An increase in volatility of the common stock during that period and the large number of outstanding warrants also had an impact on the large unrealized loss for the nine months ended September 30, 2017.

### ***Financing Expense***

We incurred approximately \$333,000 and \$313,000 of financing expenses during the nine months ended September 30, 2017, and 2016, respectively related to our registered direct offerings in June 2017, September 2016 and March 2016. We incurred approximately \$143,000 of financing expenses during the three months ended September 30, 2016, related to our registered direct offering in September 2016. We did not incur financing expenses during the three months ended September 30, 2017.

### ***Net Loss***

As a result of the above, net loss for the three and nine months ended September 30, 2017 was approximately \$1,038,000 and \$21,702,000, or \$0.04 and \$0.83 per share, respectively, compared to approximately \$2,867,000 and \$8,782,000, or \$0.13 and \$0.42 per share, respectively, for the three and nine months ended September 30, 2016. As previously discussed, included in the net loss for the three and nine months ended September 30, 2017 are non-cash charges of approximately \$3,121,000 and (\$9,048,000) in unrealized gains (losses) on the fair value of warrants, compared to unrealized gains of \$968,000 and \$3,942,000 for the three and nine months ended September 30, 2016.

## **Research and Development Projects**

Research and development costs are expensed as incurred. These costs consist primarily of salaries and related personnel costs, costs to acquire pharmaceutical products and product rights for development and amounts paid to contract research organizations, hospitals and laboratories for the provision of services and materials for drug development and clinical trials. Costs incurred in obtaining the license rights to technology in the research and development stage that have no alternative future uses are expensed as incurred. Our research and development programs are related to our oncology clinical stage drug candidates, RX-3117, Supinoxin and Archexin, and our pre-clinical stage drug candidate, RX-21101. As we expand our clinical studies, we expect to enter into additional development agreements. Significant additional expenditures will be required if we complete our clinical trials, start new trials, apply for regulatory approvals, continue development of our technologies, expand our operations and bring our products to market. The eventual total cost of each clinical trial is dependent on a number of uncertainties such as trial design, the length of the trial, the number of clinical sites and the number of patients. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive and uncertain. Because the successful development of our most advanced drug candidates, RX-3117, Supinoxin and Archexin, is uncertain, and because RX-21101 is in early-stage development, we are unable to estimate the costs of completing our research and development programs, the timing of bringing such programs to market and, therefore, when material cash inflows could commence from the sale of these drug candidates, if any. If these projects are not completed as planned, our results of operations and financial condition would be negatively affected.

### *RX-3117*

RX-3117 is a novel, investigational oral small molecule nucleoside compound. We believe RX-3117 has therapeutic potential in a broad range of cancers including pancreatic, bladder, cervical, non-small cell lung cancer and colon cancer. We previously identified the MTD of RX-3117, which we are evaluating in Phase IIa proof-of-concept clinical trials in patients with relapsed or refractory metastatic pancreatic cancer and patients with locally advanced or metastatic bladder cancer.

Expenses related to RX-3117 increased during the three and nine months ended September 30, 2017 compared to the same period in 2016 due to increased clinical trial and patient enrollments resulting from the progression of our pancreatic and bladder cancer clinical trials, as well as manufacturing costs for new campaigns. We expect that expenses related to RX-3117 will increase in the remainder of 2017 compared to the three and nine months ended September 30, 2017 due to patient enrollment costs, continued manufacturing costs for new campaigns, and the commencement of a combination Phase IIa clinical trial with Abraxane in pancreatic cancer.

### *Supinoxin (RX-5902)*

Supinoxin is a potential first-in-class small molecule inhibitor of phosphorylated p68, a protein that we believe plays a key role in cancer growth, progression and metastasis through its interaction with beta-catenin. Phosphorylated p68 results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth. In February 2017, we initiated a Phase IIa clinical study of Supinoxin in patients with metastatic TNBC.

Expenses related to Supinoxin decreased during the three and nine months ended September 30, 2017 compared to the three and nine months ended September 30, 2016. The decrease is primarily attributable to decreased manufacturing costs due to a significant supply of drug product already available from earlier manufacturing campaigns. However, we expect that expenses related to Supinoxin will increase in the remainder of 2017 compared to the three and nine months ended September 30, 2017 due to patient enrollment costs associated with our Phase IIa trial in patients with metastatic TNBC and new manufacturing campaigns.

### *Archexin*

Archexin is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. We are currently conducting a Phase IIa proof-of-concept clinical trial of Archexin in patients with metastatic RCC to evaluate its safety and efficacy in combination with AFINITOR (everolimus).

Expenses related to Archexin decreased during the three and nine months ended September 30, 2017 compared to the same periods in 2016. The decrease is primarily attributable to decreased manufacturing costs due to a significant supply of drug product already available. We expect that expenses related to Archexin will remain flat for the remainder of 2017 compared to the three and nine months ended September 30, 2017 as we continue the ongoing Archexin clinical trial.

### *Pre-clinical Pipeline*

Expenses related to our pre-clinical candidates increased for the three and nine months ended September 30, 2017 compared to the same periods in 2016 primarily as a result of increased research activities. We expect that expenses related to our pre-clinical pipeline, including RX-21101, will remain flat for the remainder of 2017 compared to the three and nine months ended September 30, 2017 as we continue testing and development.

### **Research and Development Process**

We have engaged third-party contract research organizations and other investigators and collaborators, such as universities and medical institutions, to conduct our pre-clinical studies, toxicology studies and clinical trials. Engaging third-party contract research organizations is typical practice in our industry. However, relying on such organizations means that the clinical trials and other studies described above are being conducted at external locations and that the completion of these trials and studies is not within our direct control. Trials and studies may be delayed due to circumstances outside our control, and such delays may result in additional expenses for us.

### **Liquidity and Capital Resources**

#### ***Cash Flows***

Cash used in operating activities was approximately \$11,715,000 for the nine months ended September 30, 2017. The operating cash flows during the nine months ended September 30, 2017 reflect a net loss of \$21,702,000, offset by an unrealized loss on the fair value of warrants of \$9,048,000 and a net increase of cash components of working capital and non-cash charges totaling \$939,000. Cash used in operating activities was approximately \$11,734,000 for the nine months ended September 30, 2016. The operating cash flows during the nine months ended September 30, 2016 reflect our net loss of \$8,782,000, an unrealized gain on the fair value of warrants of 3,942,000 and a net increase of cash components of working capital and other non-cash charges totaling \$990,000.

Cash used in investing activities was approximately \$6,310,000 for the nine months ended September 30, 2017, which consisted of \$15,009,000 and \$21,000 for the purchases of marketable securities and equipment, respectively, offset by \$8,720,000 from the redemption of marketable securities. Cash used in investing activities was approximately \$196,000 for the nine months ended September 30, 2016, which consisted of \$8,748,000 and \$8,000 for the purchases of marketable securities and equipment, respectively offset by \$8,560,000 from the redemption of marketable securities.

Cash provided by financing activities was approximately \$14,673,000 for the nine months ended September 30, 2017, which consisted of net proceeds of \$9,241,000 from our registered direct public offering in June 2017 and \$5,354,000 and \$78,000 from the exercise of stock warrants and options, respectively. Cash provided by financing activities was approximately \$10,122,000 for the nine months ended September 30, 2016, which consisted of net proceeds from our registered direct public offerings in March 2016 and September 2016.

After September 30, 2017, on October 17, 2017, we closed a registered direct public offering of 3,265,309 shares of common stock and warrants to purchase up to 1,632,654 shares of common stock, resulting in gross proceeds to us of approximately \$8,000,000.

### ***Contractual Obligations***

We have a variety of contractual obligations, as more fully described in our 2016 Form 10-K. These obligations include, but are not limited to, contractual obligations in connection with license agreements (including related milestone payments), lease payments, employee compensation and incentive program expenses, and contracts with various vendors for services. As of September 30, 2017, the total estimated cost to complete our contracts with vendors for research and development services was approximately \$10,750,000 under the terms of the applicable agreements. All of these agreements may be terminated by either party upon appropriate notice as stipulated in the respective agreements.

### ***Current and Future Financing Needs***

We have incurred negative cash flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts in connection with implementing our business strategy, including our planned product development efforts, our clinical trials and our research and development efforts. We will need to raise additional capital through public or private equity or debt offerings or through arrangements with strategic partners or other sources in order to continue to develop our drug candidates. There can be no assurance that additional capital will be available when needed or on terms satisfactory to us, if at all. If we are not able to raise sufficient additional capital, we will have to reduce our research and development activities. We believe our cash, cash equivalents, and marketable securities will be sufficient to cover our cash flow requirements for our current activities for at least the next 12 months from the date these financial statements were issued.

The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:

- the progress of our product development activities;
- the number and scope of our product development programs;
- the progress of our pre-clinical and clinical trial activities;
- the progress of the development efforts of parties with whom we have entered into collaboration agreements;

- our ability to maintain current collaboration programs and to establish new collaboration arrangements;
- the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and
- the costs and timing of regulatory approvals.

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements or holdings in variable interest entities.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

For quantitative and qualitative disclosures about market risk, refer to “Quantitative and Qualitative Disclosures About Market Risk” in our 2016 Form 10-K. Our exposures to market risk have not changed materially since December 31, 2016.

**Item 4. Controls and Procedures.**

*Disclosure Controls and Procedures*

Under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our CEO and CFO concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC’s”) rules and forms and (ii) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

*Changes in Internal Control Over Financial Reporting*

There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **PART II. Other Information**

### **Item 1A. Risk Factors.**

Investing in our stock involves a high degree of risk. In addition to the other information set forth in this report, you should carefully consider the factors set forth in the Risk Factors section of our 2016 Form 10-K, as well as other information contained in the 2016 Form 10-K and in other reports we file with the SEC. We do not believe that there have been any material changes to the risk factors disclosed in our 2016 Form 10-K.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

Pursuant to a consulting agreement, we issued 7,500 shares of common stock during the three months ended September 30, 2017 to a privately held investor relations firm in consideration for investor relations services. The shares of common stock were not registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the exemption from registration requirements provided by Section 4(a)(2) of the Securities Act, as a transaction not involving a public offering.

### **Item 6. Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">4.1</a>	Form of Warrant, filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed on October 13, 2017, is incorporated herein by reference.
<a href="#">10.1</a>	Form of Securities Purchase Agreement, dated as of October 13, 2017, by and between Rexahn Pharmaceuticals, Inc. and the purchasers identified on the signature pages thereto, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 13 2017, is incorporated herein by reference.
<a href="#">31.1</a>	Certification of Chief Executive Officer pursuant to Rules 13a-14(a) / 15d-14(a)
<a href="#">31.2</a>	Certification of Chief Financial Officer pursuant to Rules 13a-14(a) / 15d-14(a)
<a href="#">32.1</a>	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
<a href="#">32.2</a>	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101	The following materials from Rexahn Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q, formatted in Extensible Business Reporting Language ("XBRL"): (i) Condensed Balance Sheet; (ii) Condensed Statement of Operations; (iii) Condensed Statement of Comprehensive Loss; (iv) Condensed Statement of Cash Flows; and (v) Notes to the Financial Statements.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REXAHN PHARMACEUTICALS, INC.  
(Registrant)

Date: November 3, 2017

By: /s/ Peter D. Suzdak  
Peter D. Suzdak  
Chief Executive Officer  
(principal executive officer)

Date: November 3, 2017

By: /s/ Tae Heum Jeong  
Tae Heum Jeong  
Chief Financial Officer and Secretary  
(principal financial and accounting officer)



**CERTIFICATION PURSUANT TO RULES 13A-14(D)  
AND 15D-14(D)**

I, Peter D. Suzdak, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rexahn Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 3, 2017

/s/ Peter D. Suzdak

\_\_\_\_\_  
Peter D. Suzdak

Chief Executive Officer

---

**CERTIFICATION PURSUANT TO RULES 13A-14(D)  
AND 15D-14(D)**

I, Tae Heum Jeong, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rexahn Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 3, 2017

/s/ Tae Heum Jeong

\_\_\_\_\_  
Tae Heum Jeong  
Chief Financial Officer

---

CERTIFICATION OF  
CHIEF EXECUTIVE OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350

**SECTION 1350 CERTIFICATION\***

In connection with the Quarterly Report of Rexahn Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Peter D. Suzdak, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 3, 2017

By: /s/ Peter D. Suzdak  
Peter D. Suzdak,  
Chief Executive Officer

\* This Certification is being furnished as required by Rule 13a-14(b) under the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code, and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. This Certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise stated in such filing.

A signed original of this written statement required by 18 U.S.C. § 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

CERTIFICATION OF  
CHIEF FINANCIAL OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350

**SECTION 1350 CERTIFICATION\***

In connection with the Quarterly Report of Rexahn Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Tae Heum Jeong, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 3, 2017

By: /s/ Tae Heum Jeong

Tae Heum Jeong,  
Chief Financial Officer

\* This Certification is being furnished as required by Rule 13a-14(b) under the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code, and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. This Certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise stated in such filing.

A signed original of this written statement required by 18 U.S.C. § 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.